The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
OPEN Lancet | 17 Mar 2012
AD Hingorani and JP Casas
A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.
- Facebook likes*
- News coverage*
- SC clicks
- Osteoclast, Ciliary neurotrophic factor, Immune system, Interleukin, Interleukin-6 receptor, Tocilizumab, Interleukin 6, Rheumatoid arthritis
- MeSH headings
- Antibodies, Monoclonal, Humanized, Coronary Disease, Gene Frequency, Genetic Association Studies, Genetic Variation, Genotype, Humans, Inflammation Mediators, Mendelian Randomization Analysis, Phenotype, Polymorphism, Single Nucleotide, Randomized Controlled Trials as Topic, Receptors, Interleukin-6, Signal Transduction, Treatment Outcome
* Data courtesy of Altmetric.com